Repligen stock

RGEN · NASDAQ · USD

Compare Repligen
$165.39Change from previous close: −1.43%Absolute change: −$2.40

Close · November 16, 2026

Price history

+11.00% over the period

1 year: from $149.00 (November 17, 2025) to $165.39 (November 16, 2026), +11.00%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$165.39
October 30, 2026$176.94
September 30, 2026$192.23
August 31, 2026$180.98
July 31, 2026$141.01
June 30, 2026$136.44
May 29, 2026$123.95
April 30, 2026$118.31
March 31, 2026$117.82
February 27, 2026$128.73
January 30, 2026$149.37
December 31, 2025$163.86
November 28, 2025$171.02
November 17, 2025$149.00

At a glance

  • The company

    Develops and commercializes bioprocessing technologies and systems for biopharmaceutical, life sciences and diagnostics companies

  • Latest results

    Quarter to September 30, 2026 · EPS $0.53 (estimate $0.46)

TickerLandia's take on Repligen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$100.99
52-wk high$198.87

−16.84% from the 52-week high

Analysts · 20 analysts

Average target$203.21+22.87% vs. price

Buy 16 · Hold 4 · Sell 0 · Buy

TickerLandia Fingerprint: Repligen

Compared with similar companies: very low earnings stability, very high price, and very low profitability.

Financials and price compared with 34 companies in the medical instruments & supplies industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Repligen is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Repligen's P/E today is 192.3, in line with the median of its last 5 fiscal years (172.6; between 52.3 and 285.4 from 2020 to 2025). Repligen's Forward P/E: 63.3, +261% against the median of a group of 11 similar companies (17.5).

P/E compared with its history

Compared with 11 similar companies

Repligen's metrics compared with similar companies
MetricRepligenPosition in the groupBand
Forward P/E63.3High
Operating margin8.1%Middle
ROE-0.6%Low
Debt/equity0.33Middle
Price/book4.55High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Repligen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$209.31M

Latest quarter · Q3 2026

Net income

-$38.43M

Latest quarter · Q3 2026

Quarterly net margin

-18.4%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$10.73B
EPS
-$0.21
Volume
510.11K
Daily trading
€200.93M
Dividend yield
0.00%

How Repligen is changing

All results
  • Revenue grew 15.0% a year on average over the last 5 years

  • Operating margin fell from 28.0% to 7.5%

  • Shares outstanding up 5.0% in 5 years

Returns

Repligen returns

$1,000 invested in Repligen 5 years ago, on November 16, 2021, would be worth $615 today: −38.51% in total, −9.27% per year. This is the price return only: dividends are excluded.

PeriodRepligenS&P 500$1,000 becomes
1 month−5.72%−3.12%$943
6 months+60.78%+2.07%$1,608
Year to date+0.93%+10.46%$1,009
1 year+11.00%+13.33%$1,110
3 years+9.16%+67.73%$1,092
5 years−38.51%+60.86%$615
10 years+416.36%+247.35%$5,164

Over the last 6 months it has done better than 92% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Repligen: technical analysis

Repligen shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 49.0% below its highest close since January 2, 1990 ($324.21, September 23, 2021).

Trend
No clear trend
RSI (14 sessions)
42
Between 30 and 70
vs 200-session average
+13.79%

Support and resistance

Price areas where Repligen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$188.59+14.03%3 touches, last on October 29, 2026
  2. Resistance$174.88+5.74%3 touches, last on January 22, 2026
  3. Last price$165.39
  4. Support$163.01−1.44%2 touches, last on October 27, 2026
  5. Support$156.91−5.13%3 touches, last on October 8, 2026
  6. Support$151.32−8.51%3 touches, last on July 28, 2026

Volatility and risk

Over the last year it has moved more than the S&P 500.

Beta (1 year) vs S&P 500
1.22
Volatility (60 sessions, annualised)
48.9%
Largest fall in the last year
−40.28%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Repligen: seasonality

Average monthly price change over 37 years

+9.2%Jan+1.4%Feb+2.9%Mar−0.4%Apr+4.7%May−0.8%Jun+3.5%Jul+5.0%Aug−3.7%Sep+4.8%Oct+3.2%Nov−1.6%Dec

Over the last 37 years, the strongest month for Repligen has been January: +9.16% on average, positive in 23 years out of 36. The weakest has been September: −3.68% on average, positive in 14 years out of 37. November, the current month, has been positive in 16 years out of 36 (+3.16% on average).

Show chart data
MonthAverageMedianPositive years
January+9.16%+8.15%23 of 36
February+1.38%−2.32%14 of 37
March+2.92%+1.94%19 of 37
April−0.38%+0.42%19 of 37
May+4.65%+3.10%21 of 37
June−0.82%−0.48%18 of 37
July+3.49%+2.63%20 of 37
August+5.00%+3.51%24 of 37
September−3.68%−0.29%14 of 37
October+4.76%+0.52%19 of 37
November+3.16%−1.42%16 of 36
December−1.63%−3.42%15 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Repligen and its competitors

Biologic drug makers, contract manufacturers, diagnostic firms and bench-level researchers make up the customer base of Repligen Corporation, which develops bioprocessing technologies and systems in North America, Europe and the Asia Pacific region. Its offering spans filtration units such as cell retention systems and tangential flow cassettes, chromatography columns used to purify biological drugs, Protein A ligands, cell culture growth factors, ELISA kits, and process analytics instruments that monitor critical production parameters in real time. Products are sold under brands including OPUS, XCell, KrosFlo and SoloVPE.

Headquarters
Waltham, United States
Employees
2,000
Founded
1981
Chief executive
Olivier Loeillot
Repligen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
RepligenRGEN$10.73B8.1%—+60.78%
AvantorAVTR$10.46B8.0%30.9+103.35%
Align TechnologyALGN$11.86B19.6%24.5+6.03%
Cooper CompaniesCOO$11.91B12.9%21.5+5.44%
AptarGroupATR$9.12B12.4%34.4+25.58%
Baxter InternationalBAX$13.39B7.6%—+48.76%

Same industry or related industries, similar size. Compare Repligen with its competitors · Full profile